Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24398649 | 0.82 | TSHR (0.67) | TSHRALDH1A1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL15720852 | 0.82 | TSHR (0.56) | TSHRALDH1A1SMN1; SMN2KDM4ENPSR1 | |
| SCHEMBL27289111 | 0.81 | NPC1 (0.56) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL16150299 | 0.79 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL16106244 | 0.79 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL16106495 | 0.79 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL15516520 | 0.79 | CHRNB4 (0.52) | TSHRALDH1A1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL30695917 | 0.79 | KDM4E (0.54) | TSHRALDH1A1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL29739432 | 0.79 | CHRNB4 (0.52) | TSHRALDH1A1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL15720773 | 0.79 | LMNA (0.47) | TSHRALDH1A1SMN1; SMN2KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981535-B1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | TOPIVERT PHARMA LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-10435361-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-08 | — | — | US | disclosed |
| US-20180044288-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-9790174-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9732063-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-20160376232-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-12-29 | — | — | US | disclosed |
| US-9481648-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2016-11-01 | — | — | US | disclosed |
| EP-2925742-B1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-10-26 | — | — | EP | disclosed |
| EP-2981535-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | Respivert Limited (GB) | 2016-02-10 | — | — | EP | disclosed |
| US-20150329523-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| EP-2925742-A1 | KINASE INHIBITORS | Respivert Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-20150166483-A1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2015-06-18 | — | — | US | disclosed |
| WO-2014162126-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-10-09 | — | — | WO | disclosed |
| US-20140296208-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2014076484-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044288-A1 | KINASE INHIBITORS | SYK, LYN, BTK | TSHR 1512/4885ALDH1A1 4408/4885SMN1; SMN2 4352/4885 |
| US-20160376232-A1 | KINASE INHIBITORS | LYN, SYK, LCK | TSHR 3901/4885ALDH1A1 3120/4885SMN1; SMN2 4107/4885 |
| US-20150166483-A1 | KINASE INHIBITORS | LCK, SYK, FYN | TSHR 3858/4885ALDH1A1 4277/4885SMN1; SMN2 4668/4885 |
| US-20150329523-A1 | KINASE INHIBITORS | SYK, SRC, BTK | TSHR 1905/4885ALDH1A1 4202/4885SMN1; SMN2 4223/4885 |
| US-10435361-B2 | Kinase inhibitors | SYK, LYN, BTK | TSHR 1512/4885ALDH1A1 4408/4885SMN1; SMN2 4352/4885 |
| US-20140296208-A1 | KINASE INHIBITORS | SYK, LYN, BTK | TSHR 1512/4885ALDH1A1 4408/4885SMN1; SMN2 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.